Radiopharmaceutical developer Molecular Insight Pharmaceuticals of Cambridge, MA, has hired an interim CEO and board chairman, the company said.
Effective immediately, John Babich, president and chief scientific officer of Insight, will replace David S. Barlow as interim CEO and chairman of the board. Insight has begun a search for a permanent CEO.
Related Reading
Molecular Insight touts Trofex studies, June 18, 2008
Molecular Insight starts Trofex trial, June 12, 2008
Molecular Insight's revenue decreases in Q1, May 14, 2008
Molecular Insight launches new Azedra trials, May 1, 2008
Molecular Insight raises $150 million, November 12, 2007
Copyright © 2008 AuntMinnie.com